drugset / Trial / NCT04317001

Treatment for Cognitive Impairment in Depression

NCT04317001

Phase 3 Withdrawn Stanford University
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The proposed study seeks to investigate the effects of modafinil on cognitive function in depression, which holds promise for better treating cognitive impairment in depression, as well as better understand cognitive dysfunction in MDD from a neural rather than diagnostic point of view to better classify and treat these disabling symptoms.

Timeline

Start
2018-12-01
Primary completion
2022-11-30
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Modafinil Small molecule 100 mg